Lilly launches the Zepbound KwikPen at the same self-pay price as the vial

Eli Lilly said on February 23, 2026 that the FDA approved a label expansion for Zepbound (tirzepatide) to include a four-dose, single-patient-use KwikPen that delivers a full month of treatment in one device ^[1][3]. Patients paying cash through LillyDirect can now get any Zepbound dose in either the KwikPen or the single-dose vial at the same prices, starting at $299 per month for the 2.5 mg starting dose ^[1].

The price structure is identical across both presentations: $299 a month for 2.5 mg, $399 for 5 mg, and $449 for 7.5 mg, 10 mg, 12.5 mg and 15 mg ^[2][4]. The $449 figure is not the regular price. It comes from the Zepbound Self Pay Journey Program, and Lilly's terms say patients automatically receive the $449 purchase offer on their first purchase of a 7.5 mg or higher vial or KwikPen "beginning February 23, 2026" ^[2]. To keep it, a refill must be purchased within 45 days of the delivery or receipt date of the previous fill ^[2][4].

Miss that window and the regular self-pay prices apply: $499 for 7.5 mg and $699 each for 10 mg, 12.5 mg and 15 mg ^[2][4]. A "month" is defined as 28 days and either four single-dose vials or one KwikPen ^[2]. The KwikPen savings card can be used for up to 11 prescription fills per calendar year and expires on December 31, 2026 ^[2].

The two formats are not identical in every way. The KwikPen requires a separate pen needle purchase, while the vial requires needles and syringes ^[4]. The vial is exclusively available through LillyDirect and is self-pay only, while the KwikPen accepts select insurance as well as self-pay and can be picked up or delivered ^[4]. A separate single-dose pen remains the insurance-covered option, with eligible commercially insured patients paying as low as $25 a month; government beneficiaries are excluded ^[2][4]. Eligible Medicare Part D patients may pay no more than $50 a month under the Medicare GLP-1 Bridge program, subject to clinical criteria and plan exclusions ^[2].

The KwikPen is not a new device. Reuters notes it is also used for Lilly's diabetes drug Mounjaro and is sold in markets including the United Kingdom, Australia, the Middle East and Canada ^[3]. Novo Nordisk's Wegovy (semaglutide) has been sold in the U.S. as a single-dose weekly autoinjector since 2021 ^[3].

Why it matters for patients

Until now, the cheapest cash route for Zepbound generally meant drawing doses from vials with a syringe. The KwikPen gives self-pay patients a multi-dose pen option without paying more than the vial price at the same dose ^[1][2]. That removes cost as the deciding factor between the two and leaves the choice to convenience, comfort with syringes, and supplies.

The 45-day refill rule matters financially. For someone at 10 mg or above, letting a refill lapse moves the price from $449 to $699 a month, a $250 difference ^[2][4]. Lilly also states it can terminate, revoke or amend the purchase offer and card terms at any time, without notice, for any reason ^[2].

The self-pay card is for cash payers only. Users must attest they will not seek reimbursement from insurance or any state or federal health program, or apply the cost toward a deductible ^[2]. Lilly says over 1 million patients used LillyDirect in 2025, and that one of every three new patients starting a branded weight management medicine was prescribed Zepbound self-pay vials that year ^[1].

What happens next

On March 16, 2026, Lilly said KwikPen self-pay pricing expanded beyond LillyDirect to major pharmacies nationwide through a new KwikPen Self-Pay Savings Card, starting at $299 for 2.5 mg ^[5]. Lilly specified that card applies only to the KwikPen, not to single-dose vials or the single-dose pen ^[5]. Whether prices hold past the card's December 31, 2026 expiration is not stated in these sources ^[2].